Literature DB >> 17268214

British hypertension society recommends that beta-blockers are no longer indicated as initial treatment of hypertension: has the pendulum swung too far?

Michael J Bloch.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17268214      PMCID： PMC8109861          DOI： 10.1111/j.1524-6175.2007.06312.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  10 in total

1.  Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.

Authors:  Björn Dahlöf; Peter S Sever; Neil R Poulter; Hans Wedel; D Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2005 Sep 10-16       Impact factor: 79.321

2.  Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study.

Authors:  Bryan Williams; Peter S Lacy; Simon M Thom; Kennedy Cruickshank; Alice Stanton; David Collier; Alun D Hughes; H Thurston; Michael O'Rourke
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

3.  The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure.

Authors: 
Journal:  Arch Intern Med       Date:  1997-11-24

4.  Atenolol in hypertension: is it a wise choice?

Authors:  Bo Carlberg; Ola Samuelsson; Lars Hjalmar Lindholm
Journal:  Lancet       Date:  2004 Nov 6-12       Impact factor: 79.321

5.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

6.  2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension.

Authors: 
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

8.  Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party.

Authors: 
Journal:  BMJ       Date:  1992-02-15

9.  The ASCOT trial.

Authors:  Marvin Moser
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-12       Impact factor: 3.738

10.  The ASCOT Trial--are beta-blockers still useful as antihypertensive medication?

Authors:  Marvin Moser; Thomas D Giles; Thomas G Pickering; Ronald G Victor
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-10       Impact factor: 3.738
  10 in total
  1 in total

1.  Beneficial Effect of Efonidipine, an L- and T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients With Mild-to-Moderate Essential Hypertension.

Authors:  Il-Young Oh; Myung-Ki Seo; Hae-Young Lee; Soon Gil Kim; Ki-Sik Kim; Won-Ho Kim; Min Soo Hyon; Kyoo-Rok Han; Se-Joong Lim; Cheol-Ho Kim
Journal:  Korean Circ J       Date:  2010-10-31       Impact factor: 3.243
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.